Claude

What's Next

Hold at ₹226. Probability-weighted fair value is ₹215, implying no margin of safety at the current price. The stock is a demerger bet wrapped in a health insurance growth story, but governance scars, thin profitability, and execution risk on the restructuring timeline cap the upside unless Care Health delivers underwriting profitability within two years.

Catalyst Calendar

The next three months hinge on Q4 FY26 results, which will confirm whether the insurance business is improving its combined ratio or whether the Q3 FY26 operating loss (₹77 Cr net loss) was the start of a trend. The demerger NCLT filing in H2 2026 is the binary catalyst – any delay beyond year-end would validate the skeptics.

What the market is watching most: Care Health's combined ratio trajectory and any concrete demerger filing timeline. The stock fell 9% in the week after the demerger announcement, suggesting the market wants execution proof, not promises.